Posted by Michael Wonder on 19 Jul 2024
Diamyd Medical receives second US FDA fast track designation for Diamyd - for the prevention of type 1 diabetes
18 July 2024 - Diamyd Medical announced today that the US FDA has granted fast track designation for Diamyd (rhGAD65/alum) to treat type 1 diabetes in paediatric patients with stage 1 or stage 2 type 1 Diabetes carrying the genotype HLA DR3-DQ2.
Earlier this year, Diamyd received fast track designation for the treatment of individuals with stage 3 type 1 Diabetes carrying the HLA DR3-DQ2 genotype.
